相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Controlled extracellular proteolysis of thrombospondins
Laura Carminati et al.
MATRIX BIOLOGY (2023)
Glioblastoma remodelling of human neural circuits decreases survival
Saritha Krishna et al.
NATURE (2023)
Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma
Dong-yang Ding et al.
BRITISH JOURNAL OF CANCER (2023)
Thrombospondin-1 mimic peptide PKHB1 induced endoplasmic reticulum stress-mediated but CD47-independent apoptosis in non-small cell lung cancer
Jiani Ye et al.
DRUG DEVELOPMENT RESEARCH (2023)
Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma
Zhuochao Liu et al.
CANCER SCIENCE (2022)
Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow
Chao Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2022)
PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells
Kenny Misael Calvillo-Rodriguez et al.
ONCOIMMUNOLOGY (2022)
Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response
Elizabeth R. Stirling et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer
Zeinab Kosibaty et al.
CANCERS (2022)
Apatinib inhibits glioma cell malignancy in patient-derived orthotopic xenograft mouse model by targeting thrombospondin 1/myosin heavy chain 9 axis
Hui Yao et al.
CELL DEATH & DISEASE (2021)
Functions of Thrombospondin-1 in the Tumor Microenvironment
Sukhbir Kaur et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Targeting Ovarian Carcinoma with TSP-1:CD47 Antagonist TAX2 Activates Anti-Tumor Immunity
Albin Jeanne et al.
CANCERS (2021)
Diagnostic, Therapeutic, and Prognostic Value of the Thrombospondin Family in Gastric Cancer
Yi Lu et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2021)
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)
Philip Zeuschner et al.
CANCERS (2021)
Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer
Elie Marcheteau et al.
CANCERS (2021)
Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity
Denise Pinessi et al.
MATRIX BIOLOGY (2021)
Supramolecular attack particles are autonomous killing entities released from cytotoxic T cells
S. Balint et al.
SCIENCE (2020)
Identification of Inhibitors of Thrombospondin 1 Activation of TGF-β
Mark J. Suto et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Synaptic secretion from human natural killer cells is diverse and includes supramolecular attack particles
Ashley R. Ambrose et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Thrombospondin-1 Receptor CD47 Overexpression Contributes to P-Glycoprotein-Mediated Multidrug Resistance Against Doxorubicin in Thyroid Carcinoma FTC-133 Cells
Marie-Pierre Courageot et al.
FRONTIERS IN ONCOLOGY (2020)
Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment
Jordan Guillon et al.
CELL DEATH & DISEASE (2019)
Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors
Sukhbir Kaur et al.
FRONTIERS IN ONCOLOGY (2019)
Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation
Anthony L. Schwartz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance
Elodie Pramil et al.
BLOOD ADVANCES (2019)
Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data
Gianfranco Natale et al.
CANCER LETTERS (2018)
Soluble stroma-related biomarkers of pancreatic cancer
Andrea Resovi et al.
EMBO MOLECULAR MEDICINE (2018)
Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy
Yismeilin R. Feliz-Mosquea et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
UPRegulation of CD47 by the endoplasmic reticulum stress pathway controls anti-tumor immune responses
Katherine L. Cook et al.
BIOMARKER RESEARCH (2017)
Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis
J. P. Yang et al.
ANGIOGENESIS (2016)
Endoplasmic Reticulum Stress Protein GRP78 Modulates Lipid Metabolism to Control Drug Sensitivity and Antitumor Immunity in Breast Cancer
Katherine L. Cook et al.
CANCER RESEARCH (2016)
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients
Teresa Di Desidero et al.
INVESTIGATIONAL NEW DRUGS (2016)
Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors
Chiara Foglieni et al.
SCIENTIFIC REPORTS (2016)
Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
Andrea Camerini et al.
BMC CANCER (2015)
Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer
Samantha Russell et al.
FASEB JOURNAL (2015)
Decrease of Let-7f in Low-Dose Metronomic Paclitaxel Chemotherapy Contributed to Upregulation of Thrombospondin-1 in Breast Cancer
Wei-Yang Tao et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2015)
CD47 Receptor Globally Regulates Metabolic Pathways That Control Resistance to Ionizing Radiation
Thomas W. Miller et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Maintenance chemotherapy in children with ALL exerts metronomic-like thrombospondin-1 associated anti-endothelial effect
Nicolas Andre et al.
ONCOTARGET (2015)
CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy
David R. Soto-Pantoja et al.
CANCER RESEARCH (2014)
A Novel Cancer Therapeutic Using Thrombospondin 1 in Dendritic Cells
Tzu-Yang Weng et al.
MOLECULAR THERAPY (2014)
Txr1: an important factor in oxaliplatin resistance in gastric cancer
Jingtao Bi et al.
MEDICAL ONCOLOGY (2014)
Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma
Aparna Jayachandran et al.
ONCOTARGET (2014)
Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis
Li Jia et al.
CANCER LETTERS (2013)
Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
Marta Vives et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis
Daniel J. Lindner et al.
MATRIX BIOLOGY (2013)
Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation
Thomas W. Miller et al.
MATRIX BIOLOGY (2013)
Thrombospondin-1 Signaling through CD47 Inhibits Self-renewal by Regulating c-Myc and Other Stem Cell Transcription Factors
Sukhbir Kaur et al.
SCIENTIFIC REPORTS (2013)
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
Giacomo Allegrini et al.
ANGIOGENESIS (2012)
CD47 deficiency confers cell and tissue radioprotection by activation of autophagy
David R. Soto-Pantoja et al.
AUTOPHAGY (2012)
Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance
A. Radziwon-Balicka et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Metronomic Ceramide Analogs Inhibit Angiogenesis in Pancreatic Cancer through Up-regulation of Caveolin-1 and Thrombospondin-1 and Down-regulation of Cyclin D1
Guido Bocci et al.
NEOPLASIA (2012)
Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy
Geert C. van Almen et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2011)
Antitumor Efficacy of a Thrombospondin 1 Mimetic CovX-Body
Lingna Li et al.
TRANSLATIONAL ONCOLOGY (2011)
Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression
Xiaowei Peng et al.
ANTI-CANCER DRUGS (2010)
Quantitative Proteome Analysis of Multidrug Resistance in Human Ovarian Cancer Cell Line
Sang-Lin Li et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2010)
The Thrombospondin-1 Mimetic ABT-510 Increases the Uptake and Effectiveness of Cisplatin and Paclitaxel in a Mouse Model of Epithelial Ovarian Cancer
Nicole E. Campbell et al.
NEOPLASIA (2010)
Induction of thrombospondin-I partially mediates the anti-angiogenic activity of dexrazoxane
S. L. Maloney et al.
BRITISH JOURNAL OF CANCER (2009)
5-FU pretreatment potentiates cisplatin-induced apoptosis through up-regulation of thrombospondin-1 in head and neck squamous cell carcinomas
Bei Xu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Tumoral Expression of TXR1 and TSP1 Predicts Overall Survival of Patients with Lung Adenocarcinoma Treated with First-line Docetaxel-Gemcitabine Regimen
Chara Papadaki et al.
CLINICAL CANCER RESEARCH (2009)
De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma
Geraldine Rath et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer
James Greenaway et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 Signaling
Justin B. Maxhimer et al.
SCIENCE TRANSLATIONAL MEDICINE (2009)
Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury
Jeff S. Isenberg et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
G. Allegrini et al.
BRITISH JOURNAL OF CANCER (2008)
Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil
Hong-Ye Zhao et al.
CANCER RESEARCH (2008)
Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma
Laurence H. Baker et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
Andrea Molckovsky et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2008)
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model
Berta Laquente et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow
Jeff S. Isenberg et al.
NEOPLASIA (2008)
Thrombospondin/CD47 interaction:: A pathway to generate regulatory T cells from human CD4+CD25- T cells in response to inflammation
Philippe Grimbert et al.
JOURNAL OF IMMUNOLOGY (2006)
The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin
JE Damber et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes
Chih-Jian Lih et al.
GENES & DEVELOPMENT (2006)
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizurnab in metastatic colorectal cancer
AM Jubb et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression
Y Hamano et al.
CANCER RESEARCH (2004)
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
G Bocci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The mechanism of CD47-dependent killing of T cells:: Heterotrimeric Gi-dependent inhibition of protein kinase A
PP Manna et al.
JOURNAL OF IMMUNOLOGY (2003)
Interactions of thrombospondins with α4β1 integrin and CD47 differentially modulate T cell behavior
ZQ Li et al.
JOURNAL OF CELL BIOLOGY (2002)
分享论文
